Ann Marie Rossi

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer

Kanak Raina, Jing Lü, Yimin Qian et al. · Proceedings of the National Academy of Sciences · 2016 · 805 citations · Full text

Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871

Bruce D. Cohen, Deborah A. Baker, Catherine Soderstrom et al. · Clinical Cancer Research · 2005 · 361 citations · Full text

Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase

Kevin Currie, Jeffrey E. Kropf, Tony Lee et al. · Journal of Medicinal Chemistry · 2014 · 167 citations · Full text

Orally Efficacious Inhibitor, Drug Target, Immunology +18

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Jean S. Beebe, Jitesh P. Jani, Elisabeth Knauth et al. · PubMed · 2003 · 128 citations

Cancer Therapy, Pharmacological Characterization, Tumor Biology +21

Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity

Michael J. Munchhof, Jean S. Beebe, Jeffery M. Casavant et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 96 citations · Full text

Medicinal Chemistry, Medicine, Vegfr-2 Kinase Activity +7